Literature DB >> 18245269

Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.

Soichiro Matsushima1, Kazuya Maeda, Hisamitsu Hayashi, Yasuyuki Debori, Alfred H Schinkel, John D Schuetz, Hiroyuki Kusuhara, Yuichi Sugiyama.   

Abstract

Fexofenadine (FEX) is mainly eliminated from the liver into bile in unchanged form. We demonstrated previously that organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 are involved in the hepatic uptake of FEX. However, little is known about the mechanisms controlling the hepatic efflux of FEX from the liver to bile and blood. In the present study, the involvement of hepatic efflux transporters in the pharmacokinetics of FEX was investigated in both in vitro and in vivo studies. Vectorial transport of FEX was observed in OATP1B3/human bile salt export pump (hBSEP) double transfectants but not in OATP1B3/human breast cancer resistance protein double transfectants, which indicates the possible contribution of hBSEP to the biliary excretion of FEX in humans. In multidrug resistance-associated protein 2 (Mrp2)(-/-) mice, the biliary excretion clearance based on the plasma concentration and the liver-to-plasma concentration ratio significantly decreased, whereas the biliary excretion clearance based on the liver concentration decreased only with 20%, suggesting the minimum contribution of Mrp2 to its biliary excretion. ATP-dependent transport of FEX was observed in hMRP3-enriched membrane vesicles but not hMRP4. In Mrp3(-/-) mice, the biliary excretion clearance based on both the plasma and liver concentration and the liver-to-plasma concentration ratio increased, suggesting the significant contribution of Mrp3 to its sinusoidal efflux and the up-regulation of its biliary excretion in Mrp3(-/-) mice. On the other hand, pharmacokinetics of FEX remained unchanged in Mrp4(-/-) mice. This information provides a novel insight into the transporters important for FEX disposition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245269     DOI: 10.1124/mol.107.041459

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

2.  Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-08-11       Impact factor: 3.739

Review 3.  Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Authors:  Rebecca R Crawford; Praveen K Potukuchi; Erin G Schuetz; John D Schuetz
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

4.  Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Authors:  E D Kharasch; D Whittington; D Ensign; C Hoffer; P S Bedynek; S Campbell; K Stubbert; A Crafford; A London; T Kim
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

5.  Basolateral efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3) facilitates intestinal absorption of folates in mouse.

Authors:  Yoshiaki Kitamura; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2010-02-11       Impact factor: 4.200

6.  The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.

Authors:  Friedrich Horak; Petra Zieglmayer; René Zieglmayer; Patrick Lemell
Journal:  Inflamm Res       Date:  2009-11-27       Impact factor: 4.575

7.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

8.  Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Authors:  Evan D Kharasch; Kristi Stubbert
Journal:  Drug Metab Dispos       Date:  2013-09-25       Impact factor: 3.922

9.  Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.

Authors:  Melonie L Stanton; Melanie S Joy; Reginald F Frye
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-12-24       Impact factor: 3.205

10.  Identification of Ginkgo biloba as a novel activator of pregnane X receptor.

Authors:  Eugene Y H Yeung; Tatsuya Sueyoshi; Masahiko Negishi; Thomas K H Chang
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.